The present disclosure relates to an organic electroluminescent compound, and an organic electroluminescent material and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure has excellent color purity, solubility, and thermal stability. By comprising the organic electroluminescent compound and the organic electroluminescent material of the present disclosure, an organic electroluminescent device showing low driving voltage, excellent current and power efficiencies, and significantly improved lifespan can be provided.

An oxime ester compound represented by general formula (I):

##STR00001##

wherein R.sup.1, R.sup.2, and R.sup.3 each independently represent R.sup.11, OR.sup.11, COR.sup.11, SR.sup.11, CONR.sup.12R.sup.13, or CN; R.sup.11, R.sup.12, and R.sup.13 each independently represent a hydrogen atom, an alkyl group having 1 to 20 carbon atoms, an aryl group having 6 to 30 carbon atoms, an arylalkyl group having 7 to 30 carbon atoms, or a heterocyclic group having 2 to 20 carbon atoms, R.sup.4 and R.sup.5 each independently represent R.sup.11, OR.sup.11, SR.sup.11, COR.sup.11, CONR.sup.12R.sup.13, NR.sup.12COR.sup.11, OCOR.sup.11, COOR.sup.11, SCOR.sup.11, OCSR.sup.11, COSR.sup.11, CSOR.sup.11, CN, a halogen atom, or a hydroxyl group; and a and b each independently represent 0 to 3.

An oxime ester compound represented by general formula (I):

##STR00001##

wherein R.sup.1, R.sup.2, and R.sup.3 each independently represent R.sup.11, OR.sup.11, COR.sup.11, SR.sup.11, CONR.sup.12R.sup.13, or CN; R.sup.11, R.sup.12, and R.sup.13 each independently represent a hydrogen atom, an alkyl group having 1 to 20 carbon atoms, an aryl group having 6 to 30 carbon atoms, an arylalkyl group having 7 to 30 carbon atoms, or a heterocyclic group having 2 to 20 carbon atoms, R.sup.4 and R.sup.5 each independently represent R.sup.11, OR.sup.11, SR.sup.11, COR.sup.11, CONR.sup.12R.sup.13, NR.sup.12COR.sup.11, OCOR.sup.11, COOR.sup.11, SCOR.sup.11, OCSR.sup.11, COSR.sup.11, CSOR.sup.11, CN, a halogen atom, or a hydroxyl group; and a and b each independently represent 0 to 3.

Disclosed are compounds of Formula (I)

##STR00001##

wherein: the two dotted lines represent either two single or two double bonds; Q is:

##STR00002##

R.sub.1 is F, Cl, —CN, or —CH.sub.3; R.sub.2 is Cl or —CH.sub.3; R.sub.3 is —C(CH.sub.3).sub.2OH or —CH.sub.2CH.sub.2OH; R.sub.a is H or —CH.sub.3; each R.sub.b is independently F, Cl, —CH.sub.3, and/or —OCH.sub.3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formula (I)

##STR00001##

wherein: the two dotted lines represent either two single or two double bonds; Q is:

##STR00002##

R.sub.1 is F, Cl, —CN, or —CH.sub.3; R.sub.2 is Cl or —CH.sub.3; R.sub.3 is —C(CH.sub.3).sub.2OH or —CH.sub.2CH.sub.2OH; R.sub.a is H or —CH.sub.3; each R.sub.b is independently F, Cl, —CH.sub.3, and/or —OCH.sub.3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, A, B, C′, D, E, F, G, H′, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma. ##STR00001##

The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, A, B, C′, D, E, F, G, H′, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma. ##STR00001##

The present invention relates to indoline alkaloid compounds. In particular, indoline alkaloid compounds of the invention have antibacterial activity and/or are capable of resensitizing the susceptibility of methicillin-resistant S. aureus to a β-lactam antibiotic. The present invention also relates to a method for producing and using the same.

Described herein are molecules for use in organic light emitting diodes. Example molecules comprise at least one acceptor moiety A, at least one donor moiety D, and optionally one or more bridge moieties B. Each moiety A is covalently attached to either the moiety B or the moiety D, each moiety D is covalently attached to either the moiety B or the moiety A, and each moiety B is covalently attached to at least one moiety A and at least one moiety D. Values and preferred values of moieties A, D, and B are defined herein.

Described herein are molecules for use in organic light emitting diodes. Example molecules comprise at least one acceptor moiety A, at least one donor moiety D, and optionally one or more bridge moieties B. Each moiety A is covalently attached to either the moiety B or the moiety D, each moiety D is covalently attached to either the moiety B or the moiety A, and each moiety B is covalently attached to at least one moiety A and at least one moiety D. Values and preferred values of moieties A, D, and B are defined herein.